PANOPTIC Trial

Q: The Pulmonary Nodule Plasma Proteomic Classifier (PANOPTIC) trial included all of the following clinical risk factors to differentiate between benign and malignant pulmonary nodules - EXCEPT? - select one

A) Age

B) Smoking status

C) Nodule circumference

D) Shape

E) Location

Answer: C

The multi-institutional PANOPTIC trial (published in 2018) is known for its seven components, including five clinical risk factors, and expression of two plasma proteins associated with lung cancer and cancer immune response, which can differentiate between benign and malignant pulmonary nodules with a high sensitivity of 97 percent and a high negative predictive value of 98 percent. Although experts advise further validating these findings. The seven components are:

• age
• smoking status
• nodule diameter (not circumference - choice C)
• shape
• location
• plasma protein - LG3BP
• plasma protein - C163A

#pulmonary

#oncology

References:

1. Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest. 2018 Sep;154(3):491-500. doi: 10.1016/j.chest.2018.02.012. Epub 2018 Mar 1. PMID: 29496499; PMCID: PMC6689113.